Comparative Effectiveness of Field-Treatments for Multiple Actinic
Comparative Effectiveness of Field-Treatments for Multiple Actinic
批准号:
8603196
负责人:
MARYAM Mandana ASGARI
金额:
$7.9万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-10 至 2015-12-31
关键词:
AblationAccountingActinic keratosisAffectAmbulatory CareAmericanAmericasAnatomyApoptosisBasal cell carcinomaCaliforniaCaringCellsClinicClinicalClinical MarkersClinical ResearchClinical TrialsCohort StudiesCold TherapyCombined Modality TherapyComorbidityConfounding Factors (Epidemiology)Curettage procedureCutaneous Precancerous ConditionDataDatabasesDiagnosisDirect CostsDoseDrug ExposureDysplasiaEconomic BurdenEffectivenessElectronicsEnvironmentEpidemiologyFacilities and Administrative CostsFluorouracilFutureGoalsGrowthGuidelinesHealthcareHealthcare SystemsImiquimodImmune responseIncidenceIndividualKnowledgeLesionLifeMalignant NeoplasmsMedicareMethodologyMethodsOffice VisitsOutcomePathology ReportPatientsPharmaceutical PreparationsPharmacy facilityPopulationPremalignantPreventionProceduresProviderRandomized Controlled TrialsRecordsRegimenReportingRiskSkinSkin CancerSkin CarcinomaStructural ModelsSystemThe SunTopical agentVisitbaseburden of illnesscancer diagnosiscancer riskcomparative effectivenesscompare effectivenesscostcytotoxicfollow-uphealth care deliveryhigh riskimmune functionneglectneoplasm registrynovelpreventprimary outcomepublic health relevanceresponsesecondary outcomeskin disorderskin squamous cell carcinomastandard of care
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Non-melanoma skin cancer (NMSCs) is the most common cancer in America, with over 2 million cases diagnosed annually. Despite the large population affected and resultant burden of disease, no effective chemopreventative strategies have been identified, especially among sun-damaged individuals with existing precancerous skin lesions who are at high risk of developing skin cancer. Actinic keratoses (AKs) are precancerous skin lesions that arise on sun-damaged skin and can progress to NMSCs. The two most widely used topical agents for the treatment of multiple AKs are 5- fluorouracil (5-FU) and imiquimod. Although visits for AKs accounts for over 3.7 million ambulatory care office visits per year in the US and their treatment poses a substantial financial burden to our healthcare system, costing over a billion dollars annually, no studies have compared the effectiveness of the these twp topical field-based therapies. We propose to compare the effectiveness of 5-FU and imiquimod in preventing NMSCs (primary aim) and AKs (secondary aim) using retrospective data from Kaiser Permanente Northern California (KPNC). We also seek to ascertain dose-response curves for each drug over a 5 year follow-up period. One of the unique features of the project is the setting, which allows for ascertainment of effectiveness in a real-world practice environment. KPNC also offers the added advantage of rich electronic databases, with a wealth of information of exposure (detailed pharmacy database), outcome (unique NMSC registry which identified non-reportable skin cancer), and potentially relevant co-variates. The other unique aspect of this proposal is the way in which the retrospective observational data is approached, utilizing novel biostatistical methodologies (point-treatment marginal structural models) to draw casual inference regarding the relationship between exposure and outcome as would be obtained in a clinical trial setting. These newly developed methods have not been previously used in Dermato-epidemiology. The goals of this project align with NIAMS's long-range planning goals of increasing skin related clinical research by performing "comparative effectiveness of therapies, and combination therapy approaches for skin disease treatment." By accomplishing our study aims, we can help identify the most effective topical agent among high risk individuals for the prevention of the most common cancer in America.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Patient oriented research and mentoring program in dermatologic diseases
-
批准号:10685455
-
项目类别:
-
资助金额:$19.24万
-
财政年份:2023
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Patient oriented research and mentoring program in dermatologic diseases
-
批准号:10835532
-
项目类别:
-
资助金额:$5.17万
-
财政年份:2023
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Identification of genetic loci and pathways underlying hidradenitis suppurativa risk
-
批准号:9976890
-
项目类别:
-
资助金额:$20.34万
-
财政年份:2020
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Identification of genetic loci and pathways underlying hidradenitis suppurativa risk
-
批准号:10256622
-
项目类别:
-
资助金额:$15.52万
-
财政年份:2020
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility
-
批准号:10606627
-
项目类别:
-
资助金额:$39.66万
-
财政年份:2020
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility
-
批准号:10356846
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility
-
批准号:10116335
-
项目类别:
-
资助金额:$35.5万
-
财政年份:2020
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression
-
批准号:10380108
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2019
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression
-
批准号:10836131
-
项目类别:
-
资助金额:$37.43万
-
财政年份:2019
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression
-
批准号:10115644
-
项目类别:
-
资助金额:$25.58万
-
财政年份:2019
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression
-
批准号:9916722
-
项目类别:
-
资助金额:$24.65万
-
财政年份:2019
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Patient oriented research and mentoring program in dermatologic diseases
-
批准号:10301798
-
项目类别:
-
资助金额:$19.46万
-
财政年份:2017
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Patient oriented research and mentoring program in dermatologic diseases
-
批准号:10493331
-
项目类别:
-
资助金额:$14.17万
-
财政年份:2017
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Genome-wide association study of cutaneous squamous cell carcinoma
-
批准号:8817258
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Genome-wide association study of cutaneous squamous cell carincoma
-
批准号:9014520
-
项目类别:
-
资助金额:$26.62万
-
财政年份:2013
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Genome-wide association study of cutaneous squamous cell carcinoma
-
批准号:8628805
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2013
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Comparative Effectiveness of Field-Treatments for Multiple Actinic
-
批准号:8447336
-
项目类别:
-
资助金额:$7.9万
-
财政年份:2013
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Genome-wide association study of cutaneous squamous cell carcinoma
-
批准号:8440111
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2013
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
Genome-wide association study of cutaneous squamous cell carincoma
-
批准号:9058794
-
项目类别:
-
资助金额:$34.85万
-
财政年份:2013
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
NSAID use in Chemoprevention of Squamous Cell Carcinomas
-
批准号:6874066
-
项目类别:
-
资助金额:$13.17万
-
财政年份:2005
-
负责人:MARYAM Mandana ASGARI
-
依托单位:
海外基金